EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Long-Term Experience of Tolvaptan

Pierre Antoine Brown iD, Suzy Bubolic iD, Annick Laplante iD, Thomas Jaeger iD, Ahsan Alam iD

Kidney360 · 2025

DOI: 10.34067/kid.0000000934 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney360, 2025. Verfasst von Pierre Antoine Brown und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Antidiuretic Hormone Receptor Antagonists, Chemical and Drug Induced Liver Injury, Polycystic Kidney, Autosomal Dominant, Benzazepines. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Otsuka Canada Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In Canada, tolvaptan (JINARC) is approved for the treatment of adults with autosomal dominant polycystic kidney disease to slow the progression of kidney enlargement and kidney function decline. Safety data from the pivotal Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO 3:4) study suggested the potential for increased risk of liver injury with tolvaptan, which led to the establishment of the Canadian Hepatic Safety Monitoring and Distribution Programme in 2015. This review summarizes data regarding hepatic safety from clinical trials and presents data from established risk mitigation programs and real-world evidence. Data show that frequent liver function monitoring allows timely detection of drug-induced liver injury and prompt treatment interruption. To date, this approach has led to the absence of serious liver injury or liver failure in more than 2800 patients treated with tolvaptan in Canada over the past 10 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidiuretic Hormone Receptor AntagonistsChemical and Drug Induced Liver InjuryPolycystic Kidney, Autosomal DominantBenzazepinesHumansTolvaptanCanadaLiver Function Tests

Stichwörter der Autor:innen

ADPKD

Substanzen

TolvaptanAntidiuretic Hormone Receptor AntagonistsBenzazepines

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada.
  • Otsuka Pharma GmbH, Frankfurt, Germany.
  • Division of Nephrology, McGill University Health Centre, Montreal, Quebec, Canada.

ORCID-Profile: Pierre Antoine Brown, Suzy Bubolic, Annick Laplante, Thomas Jaeger, Ahsan Alam

Förderung

  • Otsuka Canada Pharmaceutical

Zitieren

APA

Brown, P. A., Bubolic, S., Laplante, A., Jaeger, T., & Alam, A. (2025). Long-Term Experience of Tolvaptan. Kidney360. https://doi.org/10.34067/kid.0000000934

Vancouver

Brown PA, Bubolic S, Laplante A, Jaeger T, Alam A. Long-Term Experience of Tolvaptan. Kidney360. 2025. doi:10.34067/kid.0000000934

BibTeX
@article{Brown2025,
  author = {Brown, Pierre Antoine and Bubolic, Suzy and Laplante, Annick and Jaeger, Thomas and Alam, Ahsan},
  title = {Long-Term Experience of Tolvaptan},
  journal = {Kidney360},
  year = {2025},
  doi = {10.34067/kid.0000000934}
}
Kostenlos starten →